Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Alzheimer'S & Dementia (New York, N. Y.)|June 2, 2018
Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trialsSteven X Xu, Mahesh N Samtani, Alberto Russu, et al.
Chest|December 22, 2025
A prospective, multicenter, open-label, single-arm Phase 2 study to investigate the pharmacokinetics, safety, tolerability, and exploratory efficacy of selexipag in children with pulmonary arterial hypertensionMaurice Beghetti, Lene Nygaard Axelsen, Julian I Borissoff, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 2, 2018
Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumabMahesh N Samtani, Steven X Xu, Alberto Russu, et al.
Journal of Alzheimer'S Disease : JAD|May 11, 2016
Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of BapineuzumabAlberto Russu, Mahesh N Samtani, Steven Xu, et al.
Alzheimer'S Research & Therapy|May 16, 2020
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension studyGerald Novak, Johannes Rolf Streffer, Maarten Timmers, et al.
Journal of Clinical Pharmacology|March 6, 2018
Evaluating Potential QT Effects of JNJ-54861911, a BACE Inhibitor in Single- and Multiple-Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration-QTc AnalysisMaarten Timmers, Vikash Sinha, Borje Darpo, et al.
Therapeutic Advances in Infectious Disease|December 18, 2023
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirineParul Patel, Paula Teichner, Emilie Elliot, et al.
Alzheimer'S Research & Therapy|August 24, 2018
Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled studyMaarten Timmers, Johannes Rolf Streffer, Alberto Russu, et al.
The Pediatric Infectious Disease Journal|August 19, 2025
Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Switching to Oral Rilpivirine in Combination With Other Antiretroviral Therapy in Virologically Suppressed Children Living With HIV-1 Infection: Forty-eight-week Results From the Phase 2, Open-label, Single-arm, PICTURE StudyJohan Lombaard, Francis Ssali, Visal Moolasart, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitorMaarten Timmers, Bianca Van Broeck, Steven Ramael, et al.
Pageof 3